WuXi Biologics (OTCPK:WXIBF ... has agreed to sell the plant to Merck (NYSE:MRK) for around $500M, according to Reuters. In late December, WuXi Apptec (OTCPK:WUXIF) said it had agreed to sell ...

MSD has expanded its presence in Ireland with an agreement to buy a vaccine manufacturing facility from Chinese biotech WuXi Biologics for around €500 million (around $520 million). The plant in ...

Hong Kong IPO: WuXi Biologics unit eyes up to US$520 million in biotech push WuXi XDC, a 60 per cent-owned unit of WuXi Biologics, could raise as much as US$520 million, including excess share ...

January 6, 2025 China's WuXi Biologics to sell Irish vaccine facility ... April 11, 2024 Fujifilm to invest $1.2 bln in North Carolina plant in biopharma expansion Japan's Fujifilm will invest ...

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost ...

WuXi Biologics differentiates itself from other global well-established contract development and manufacturing organizations, with its “follow-and-win the molecule” and the “global dual ...

Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, March 10, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development ...

The company was ranked top in its industry and received a Top 1% S&P Global Corporate Sustainability Assessment (CSA) Score, marking the third year WuXi Biologics has received this highest level ...

WUXI, China, Feb. 26, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization ...